Discover our latest news, updates and press releases

Jumet, Belgium – February 1st, 2023 – Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO) specialized in gene therapy, vaccines, and oncolytic viruses, today announced that it has appointed Darren Leva as Chief Business Officer. Darren’s extensive commercial experience in biotherapeutics CDMOs will further extend Exothera’s business and commercial capability across existing and […]

Quantoom Biosciences S.A. (“Quantoom”), a Belgian biotech with the mission to reinvent mRNA production announces today the opening of a brand-new facility in évry-Courcouronnes (France). Following the SynHelix acquisition in 2021, Quantoom already had infrastructures in France, part of the Genopole campus, but these were no longer suitable in view of the dazzling development of […]

Boston, US, March 22, 2023 – Remedium Bio, a biotechnology company developing a lead candidate disease modifying treatment for Osteoarthritis (OA), and Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO) specialized in gene therapy, vaccines, and oncolytic viruses, reached an agreement for a collaboration to demonstrate the industrialization potential of Remedium’s AAV2-FGF18. Remedium’s […]

Charleroi, Belgium – March 23, 2022 – Exothera S.A., a CDMO specialized in the development and manufacture of viral vectors for vaccines and gene therapies, received Good Manufacturing Practices (GMP) certification from the Federal Agency for Medicines and Health Products (FAMHP) for its facilities in Jumet, Belgium. This accreditation follows a series of successful inspections […]

ImmuneWatch, Quantoom Biosciences (“Quantoom”) and UAntwerp (Lab of Experimental Hematology) are delighted to announce a public-private partnership in a project under the “Pandemic Preparedness” call, launched by the University of Antwerp in 2022. “The goal of this project is to assess if a detailed analysis of the T-cell receptor response can be utilised to inform […]

Kuopio (Finland), March 31, 2022 – Rokote Laboratories Finland Ltd., a vaccine development company focussing on a second-generation COVID-19 vaccine, and Exothera S.A. will collaborate to bring the intranasal coronavirus vaccine FINCoVac 2.0 to clinical Phase I/II trials. Exothera will finetune the industrialization of the FINCOVAC 2.0 process and manufacture clinical material for Phase I/II […]

Brussels, Belgium, April 19, 2023 – Exothera has partnered with Quantoom Biosciences (“Quantoom”) to gain access to Quantoom’s Nfinity technology, a continuous production platform for RNA. The partnership will enable Exothera to be the first CDMO in the world to offer this off-the-shelf process for the continuous production of RNA as a service. Continuous manufacturing […]

Quantoom Biosciences S.A. (“Quantoom”), a Univercells company, is proud to announce the successful shipment from Belgium and installation of the first Ntensify™ midi system for mRNA manufacturing at Afrigen Biologics in Cape Town, South Africa. This marks a significant milestone on Quantoom’s journey to radically change the way mRNA is manufactured. Part of the WHO […]

Jumet (Belgium), March 29, 2023 HE President William Ruto announces new biomanufacturing training initiative in Kenya, with Unizima, a Univercells company as its technical and industrial partner. Unizima and Univercells were honored to receive His Excellency President Ruto at their Belgian manufacturing facilities to initiate a collaboration for the establishment of a Biomanufacturing Training Hub […]

Press release: visit of His Majesty the King of the Belgians Philippe and Her Majesty the Queen of the Belgians Mathilde to Afrigen Biologics Belgian Royal delegation visits the Afrigen facilities where Univercells and Etherna will be supporting the development of the first African-owned mRNA COVID-19 vaccine. Cape Town (South Africa), March 25, 2023 – […]